<DOC>
	<DOCNO>NCT00000662</DOCNO>
	<brief_summary>To facilitate use zidovudine ( AZT ) child 3 month 12 year age HIV-infected either symptomatic CD4 cell count &lt; 400 cells/mm3 monitor adverse effect AZT . Previous study pediatric patient show improvement clinical , immunologic , virologic parameter administration AZT .</brief_summary>
	<brief_title>A Treatment IND Retrovir Brand Zidovudine ( AZT ) Therapy Pediatric Patients With HIV Disease</brief_title>
	<detailed_description>Previous study pediatric patient show improvement clinical , immunologic , virologic parameter administration AZT . This Treatment IND ( investigational new drug ) open label , uncontrolled protocol . AZT order prescribed patient 's physician . The physician responsible obtain informed consent , assure patient meet eligibility criterion , dispense medication patient , monitor patient 's condition treatment , reporting require data project coordinate center .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Treatment : Allowed : Blood transfusion hematologic toxicity . Criteria child 3 month le 15 month age : Patient must HIV antibodypositive repeat reactive screen test ( e.g. , ELISA ) positive confirmatory test ( e.g. , Western blot ) . OR If antibodynegative , patient must two positive p24 antigen determination perform least one week apart positive HIV culture . Patients must meet two follow criterion : Be HIV culture positive p24 antigen positive . Have least one Class P2 symptom ( CDC criterion ) . Be immunosuppressed define : CD4+ ( T4 ) lymphocytes = &lt; 400 cells/mm3 . Abnormal age adjust immunoglobulin level ( IgG IgA ) . Decreased helper/suppressor ratio &lt; 1.0 . Note : In general , abnormal value lab test confirm 2 measurement least 1 week apart , clinical cause abnormality rule . Criteria child 15 month 12 year age : Patient must HIV antibodypositive repeat reactive screen test ( e.g. , ELISA ) positive confirmatory test ( e.g. , Western blot ) . OR If antibodynegative , patient must two positive p24 antigen determination perform least one week apart positive HIV culture . Patients must meet one follow criterion : Have least one class P2 symptom ( CDC criterion ) . Be immunosuppressed defined CD4+ ( T4 ) lymphocytes = &lt; 400 cells/mm3 , base two measurement least 1 week apart . Exclusion Criteria Coexisting Condition : Patients know hypersensitivity AZT exclude . Patients follow exclude : Failure meet inclusion criterion . Inability obtain sign informed consent parent legal guardian . Enrollment another treatment protocol expressly prohibit concomitant treatment zidovudine ( AZT ) . Enrollment another clinical trial AZT treatment . Known hypersensitivity AZT .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 1992</verification_date>
	<keyword>Drugs , Investigational</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>